CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China

Stroke

Volumn 44, Issue 6, 2013, Pages 1717-1719

  Jia, Dong Mei ^a   Chen, Zhi Bin ^a   Zhang, Mei Juan ^a   Yang, Wen Jie ^a   Jin, Jia Li ^a   Xia, Yong Quan ^a   Zhang, Chun Lei ^b   Shao, Yuan ^a   Chen, Cong ^a   Xu, Yun ^a  

^a THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^b Nanjing Sichuang Biotechnology Co Ltd   (China)

Author keywords

Clopidogrel resistance; CYP2C19 genotype; Ischemic stroke; Stroke outcome

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; OZAGREL;

ARTICLE; BRAIN ISCHEMIA; CHINA; CYTOCHROME P450 2C19 GENE; CYTOCHROME P450 3A4 GENE; FOLLOW UP; GENE; HUMAN; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PURINERGIC P2Y12 RECEPTOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

CLOPIDOGREL RESISTANCE; CYP2C19 GENOTYPE; ISCHEMIC STROKE; STROKE OUTCOME;

AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GENETIC TESTING; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; STROKE; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84880145973     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.000823     Document Type: Article

References (7)

1. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM; FASTER Investigators. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol. 2007;6:961-969.
2. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, et al. Identifcation of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409:202-207.
3. Kubica A, Kozinski M, Grzesk G, Fabiszak T, Navarese EP, Goch A. Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis. 2011;32:459-466.
4. Ziegler S, Schillinger M, Funk M, Felber K, Exner M, Mlekusch W, et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke. 2005;36:1394-1399.
5. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-362.
6. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, et al; PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376:1320-1328.
7. Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol. 2011;57:2474-2483.